Gene Therapy Market

The secondary research process involved comprehensive analysis of regulatory databases for Advanced Therapy Medicinal Products (ATMPs), peer-reviewed biomedical journals, clinical trial registries, and gene therapy-specific professional societies. Key sources included the US Food & Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), European Medicines Agency (EMA) Committee for Advanced Therapies (CAT), National Institutes of Health (NIH) Office of Science Policy, National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov registry, World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), American Society of Gene & Cell Therapy (ASGCT), European Society of Gene & Cell Therapy (ESGCT), International Society for Cell & Gene Therapy (ISCT), National Organization for Rare Disorders (NORD), EURORDIS (European Rare Diseases Organisation), and national gene therapy regulatory directories from key markets. These sources were utilized to collect clinical trial enrollment data, regulatory approval pathways for AAV and lentiviral vectors, manufacturing capacity statistics, vector safety profiles, pricing and reimbursement frameworks for one-time curative therapies, and market landscape analysis for viral vector manufacturers and contract development manufacturing organizations (CDMOs).

In order to gather qualitative and quantitative information unique to advanced genetic therapies, supply-side and demand-side stakeholders were involved in the core study process. Heads of CMC (Chemistry, Manufacturing, and Controls), CSOs, CEOs, regulatory affairs directors with expertise in ATMP submissions, and commercial directors from gene therapy companies, viral vector producers, plasmid suppliers, and specialized CDMOs were examples of supply-side sources. Demand-side sources included pediatric geneticists overseeing rare disease protocols, procurement leads from hospitals with cell and gene therapy capabilities, pharmacy directors overseeing cold chain logistics for viral vector products, principal investigators of gene therapy clinical trials, medical directors from accredited gene therapy treatment centers, and directors of hemophilia treatment centers. Primary research confirmed clinical pipeline timelines, evaluated manufacturing capacity constraints, validated market segmentation across vector types (AAV, Lentiviral, and Non-viral), and obtained information on reimbursement negotiations, HTA (Health Technology Assessment) results, and site-of-care administration dynamics.

Primary Respondent Breakdown:

By Designation: C-level Primaries (38%), Director Level (30%), Others (32%)

By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)

Global market valuation was derived through revenue mapping, clinical trial pipeline analysis, and estimated treatment volume projections. The methodology included:

Identification of 50+ key gene therapy developers and vector manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across Adeno-associated Viral (AAV) vectors, Lentiviral vectors (LVVs), Adenoviral vectors (AdVs), Retroviral vectors, and Non-viral delivery platforms (physical and chemical methods)

Therapeutic area segmentation across oncological disorders (CAR-T and TCR therapies), rare diseases (hemophilia, inherited retinal dystrophies, muscular dystrophies), cardiovascular diseases, and neurological disorders

Analysis of reported and modeled annual revenues specific to gene therapy product portfolios and contracted manufacturing services

Coverage of manufacturers and developers representing 75-80% of global market share in 2024

Extrapolation using bottom-up (approved therapy volumes × average therapy pricing by country/region) and top-down (manufacturer revenue validation) approaches, incorporating patient eligible population modeling and treatment center capacity analysis to derive segment-specific valuations